biuro@scopefluidics.com
+48 22 376 21 14
About
Team
Our offer
Knowledge base
News
Investor relations
Contact
biuro@scopefluidics.com
+48 22 376 21 14
About
Team
Our offer
Knowledge base
News
Investor relations
Contact
biuro@scopefluidics.com
+48 22 376 21 14
RAPORT ESPI 19/2018 | 18-12-2018 | Powołanie Komitetu Doradczego
Previous Post
RAPORT ESPI 17/2018 | 29-11-2018 | Zakończenie pierwszych testów systemu Bacteromic w Narodowym Instytucie Leków
Next Post
RAPORT EBI 1/2019 | Rejestracja podwyższenia kapitału zakładowego Spółki
0
Shares
Related Posts
18.11.2024
Scope Fluidics Secures $30 Million from Conditional Payment Settlement with Bio-Rad Laboratories in Curiosity Diagnostics Sale
aj
0
24.09.2024
Scope Fluidics Signs Agreement for IVDR Certification of Innovative BACTEROMIC System
lk
0
04.09.2024
Notified Body Initiates IVDR Certification Readiness Assessment for BACTEROMIC System, Developed by Scope Fluidics Group
lk
0
×